SCHEDULE 13G/A: Ionic Ventures Exits Propanc Biopharma Stake

Ionic Ventures, LLC and its affiliates have filed an amendment to their Schedule 13G, indicating they no longer beneficially own more than 5% of Propanc Biopharma, Inc.'s common stock.

Summary

• Ionic Ventures, LLC, Ionic Management, LLC, Brendan O'Neil, and Keith Coulston (collectively, the "Reporting Persons") have filed an Amendment No. 1 to their Schedule 13G.
• The purpose of this amendment is to update beneficial ownership information, indicating that each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the outstanding shares of Propanc Biopharma, Inc.'s Common Stock.
• This filing constitutes an exit filing for each of the Reporting Persons.
• As of the filing date, none of the Reporting Persons beneficially owns any shares of Common Stock of Propanc Biopharma, Inc., representing 0% of the class.
• The original Schedule 13G was filed by the Reporting Persons on August 19, 2025.

Sentiment

Score: 5

Explanation: The filing is a factual report of a change in beneficial ownership, indicating a neutral sentiment as it does not contain performance or strategic updates for the issuer.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders may note the exit of a significant investor group, which could influence market perception.

Key Dates

Recommendation

The filing reports a significant investor, Ionic Ventures, and its affiliates, have reduced their stake in Propanc Biopharma, Inc. to below 5%, constituting an exit filing. While this is a factual reporting of a change in beneficial ownership, the departure of a major investor can introduce uncertainty. Without further information on the reasons for the divestment or the company's operational performance, a 'hold' recommendation is prudent to observe market reaction and any subsequent disclosures.

Keywords

Propanc Biopharma, Ionic Ventures, Schedule 13G, beneficial ownership, common stock, SEC filing, investor exit